Back to top
more

MannKind (MNKD)

(Delayed Data from NSDQ)

$3.75 USD

3.75
2,546,214

-0.03 (-0.79%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $3.75 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

ABCELLERA BIOLG (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate MannKind (MNKD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 33.33% and 5.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

MannKind (MNKD) Q4 Earnings Meet Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 0% and 1.48%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of MannKind (MNKD) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 45.83% and 42.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

MannKind (MNKD) Matches Q3 Earnings Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 0% and 9.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Why MannKind (MNKD) Could Beat Earnings Estimates Again

by Zacks Equity Research

MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

MannKind (MNKD) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Zacks Equity Research

Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how MannKind (MNKD) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

Zacks Equity Research

MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 400% and 15.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy

by Zacks Equity Research

MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how MannKind (MNKD) and Merck (MRK) have performed compared to their sector so far this year.

Zacks Equity Research

MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

MannKind (MNKD) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 150% and 13.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Shattuck Labs (STTK) delivered earnings and revenue surprises of 21.28% and 457.50%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.